Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...

Structure Therapeutics Inc. (NASDAQ:GPCR) was able to report positive results from its phase 2a study using its GLP-1R agonist GSBR-1290 for the treatment of patients with obesity in June 2024.

Nxera will hold an exclusive licence for the antibody assets globally, granting full rights for their development and ...

“GPCR-targeted drugs have been the most productive target class in drug discovery history, with about one-third of all FDA-approved drugs targeting these receptors. Our proprietary Native ...

The two-year-old South San Francisco-based biotech – which focuses on the development of small-molecule drugs targeting G ...

Phase 2 trial initiation in patients with sleep /wake disorders results in milestone payment of US$3.5 million to NxeraTokyo, Japan and ...

Structure Therapeutics (NASDAQ:GPCR) is a biotechnology company developing oral therapies targeting G-protein-coupled ...

Shares of “SEPN” will begin trading Friday on the Nasdaq stock exchange. GPCRs, or G protein-coupled receptors, are something of a cellular jack of all trades, involved in a range of ...

PTH1R is a G protein coupled-receptor (GPCR), part of a family of receptors that regulate a wide range of physiological processes. The role of these receptors in both health and disease is known ...

Septerna may be yet to disclose “any meaningful clinical data,” but the biotech clearly thinks there will be investor appetite for its G protein-coupled receptors (GPCRs). The South San ...

Nxera Pharma & Antiverse collaborate to design novel GPCR-targeted antibody therapeutics using generative AI: Tokyo, Japan Wednesday, November 6, 2024, 13:00 Hrs [IST] Nxera Pharm ...